

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

**NEUROENDOCRINE
DISEASE ORIENTED GROUP**

AGENDA

OPEN SESSION

Venue: Rossetti Room, Delta Chelsea Hotel, Toronto

Date: Saturday, April 28th, 2012

Time: 09:30 to 10:15 hrs

Chairs: Dr. Tim Asmis, Dr. Daniel Rayson & Dr. Hagen Kennecke

09:30	WELCOME AND INTRODUCTION	DR. H. KENNECKE, DR. T. ASMIS & DR. D. RAYSON
09:30 – 09:40	APPROVED/ACTIVE TRIALS	
	NEC.2 (CALGB 80701): RANDOMIZED PHASE II STUDY OF EVEROLIMUS ALONE VERSUS EVEROLIMUS PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMOURS	DR. H. KENNECKE
09:40 – 10:00	CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS	
	CALGB 81103: PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS	DR. T. ASMIS
10:00 – 10:15	INTERGROUP TASK FORCE UPDATE	
10:15	CLOSING REMARKS	